|
|
Post by wsulylecoug on Sept 16, 2019 16:53:41 GMT -5
If TreT was around before the pump version Martine would never have bothered with the pump version and would never have aquired the pump company. Eventually TreT will take over but in the meantime uthr has to keep pushing the pump. Today's news is about the pump which indirectly helps mnkd because it helps keep uthr in business. By virtue of the fact that someone bothered to develop an extended release tablet form, it seems that this isn't as cut and dried as you're presenting. One would conclude there are some circumstances when an extended release (ER tablet or 2 day infusion) fits the need better than inhale and rapid absorption... or so it would logically seem to me. Is UTHR actually saying that TreT will replace all these other modalities rather than just being a replacement for their existing inhaled Trep? Being a replacement for nebulized Trep (especially with potential for expanded indication) seems great opportunity even without need to spin it as replacement for the extended dosing options. Caveat, I know comparatively little about treatment regimes for PAH and when the different Trep options are used. Eager to learn more about it, though. Thanks ktim...you captured what I was trying to say earlier. PAH doesn't seem to have a silver bullet to treat all causes and stages of progression. The WHO has 5 classifications, increased from just 2 in 1973. Last classification update was done in 2013... pulmonaryhypertensionnews.com/pulmonary-hypertension-who-classification/A quote from the article..."Now the classification has been expanded to five groups, to emphasize the importance of the underlying cause of the disease. This reflects our increased knowledge of what can cause pulmonary hypertension, along with what impact this can have on disease progression and required treatment." Maybe I'm getting PAH and PH confused. Group I is PAH, Groups 2-5 are PH. Either way, I believe TreT is targeting more than just Group I. |
|
|
|
Post by uvula on Sept 16, 2019 17:12:49 GMT -5
If TreT was around before the pump version Martine would never have bothered with the pump version and would never have aquired the pump company. Eventually TreT will take over but in the meantime uthr has to keep pushing the pump. Today's news is about the pump which indirectly helps mnkd because it helps keep uthr in business. I should have been more clear. This is my opinion. Martine never said this. But of course she would never say this even if it is true. |
|
|
|
Post by wsulylecoug on Sept 16, 2019 17:47:29 GMT -5
This "good news" is for a drug that competes with mnkd's PAH drug. This is the statement that I don't quite understand. |
|
|
|
Post by uvula on Sept 16, 2019 18:39:13 GMT -5
This "good news" is for a drug that competes with mnkd's PAH drug. This is the statement that I don't quite understand. I was commenting on mytakeonit's post at the beginning of this thread. |
|
|
|
Post by letitride on Sept 16, 2019 18:47:41 GMT -5
Actually the good news is it helps patients with PAH while a better solution is in the making.
|
|
|
|
Post by radgray68 on Sept 16, 2019 21:16:50 GMT -5
I see the good news being that our next FDA drug approval candidate for PAH is being tested and paid for by one of the most knowledgeable entities on the planet in the field of PAH. This says we partnered with the guys who can get it done. Both they and the FDA will be even more knowledgeable and comfortable with these therapies than before. Perhaps when our inhaled version comes up, we get rubber stamped just that much quicker because of the abundance of recent clinical data in all methods of delivery.
|
|
